When popular genetic testing company 23andMe filed for bankruptcy earlier this year and announced it was for sale, privacy ...

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court ...

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...

Me Holding Co. secured bankruptcy court approval to sell its genetic data trove to its co-founder and a related nonprofit for ...

AndMe had “inadequate” security systems and was “slow to respond” to warning signs customers’ sensitive data was at risk ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

San Francisco-based 23andMe filed for Chapter 11 bankruptcy protection in the Eastern Missouri federal court district in ...

Genetic testing company 23andMe never hit on a sustainable business model and went bankrupt. Now, it's being sold to a ...